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  Abstract – Monoclonal B-cell lymphocytosis (MBL) is an 
asymptomatic hematologic condition defined by the presence 
of a small (<5 x 109/L) clonal B-cell population in the 
peripheral blood in the absence of lymph-node enlargement, 
cytopenias or autoimmune diseases. It is found in 
approximately 3-12% of normal persons depending on the 
accuracy of analytical techniques applied. According to the 
immunophenotypic profile of clonal B-cells, the majority of 
MBL cases (75%) are classified as chronic lymphocytic 
leukemia (CLL)-like. This form may progress into CLL at a 
rate of 1–2% per year. It is thought that CLL is always 
preceded by MBL. The remaining MBL cases are defined as 
atypical CLL-like (CD5+/CD20bright) and CD5- MBL. The 
MBL clone size is quite heterogenous. Accordingly, two 
forms of MBL are identified: i) high-count, or ‘clinical’ 
MBL, in which an evidence of lymphocytosis (<5 x 109/L 
clonal B-cells) is seen, and ii) a low-count MBL,  in which a 
normal leukocyte count is found and that is identified only in 
population-screening studies. Both forms of MBL may carry 
the cytogenetic abnormalities that are the hallmark of CLL, 
including 13q-, 17p- and trisomy 12. Consistent with the 
indolent phenotype of this condition, genetic lesions, such as 
TP53, ATM, NOTCH1 and SF3B1 mutations, usually 
associated with high-risk CLL, are rarely seen. Overall, no 
prognostic indicator of evolution of MBL to overt CLL has 
been found at present time. However, taking into account 
this possibility, a clinical and lab monitoring (at least 
annually), is recommended. 
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I.  INTRODUCTION 
 
 Monoclonal B-cell lymphocytosis, or MBL for short, 
is an asymptomatic condition characterized by the 
presence of a circulating small clonal B-lymphocyte 
population in persons who do not have chronic 
lymphocytic leukemia (CLL), other B-cell 
lymphoproliferative disorder, or underlying conditions 
such as infectious or autoimmune disorders [1].  
Despite the fact that the majority of subjects 
diagnosed with MBL does not develop CLL [2,3], a large 
population-based cancer study suggests that MBL may 
precedes CLL by several years in some cases [4]. Efforts 
are on-going to identify at molecular level patients with 
MBL at higher risk of developing CLL in order to design 
intervention approaches able to delay or prevent CLL 
progression. 
 
II.  WHAT IS MBL 
 
MBL has been defined as an asymptomatic condition 
characterized by an expansion of circulating clonal B-cell 
lymphocytes (less than 5 x 10
9
/L) in patients with no 
symptoms or signs of lymphoproliferative disorders, such 
as lymph-node enlargement a and/or hepato-splenomegaly 
(Table 1) [1,2,5-7]. Moreover, MBL may be classified as 
follows, according to the immunophenotypic profile of 
clonal cells:  
i) CLL-like phenotype (75% of cases), in which 
cells are indistinguishable from that of CLL 
cases in that they coexpress CD5, CD19, CD23, 
and CD20
dim
, and with surface immunoglobulin 
(sIg) expression at low levels;  
ii) atypical CLL phenotype: CD5 and CD19 
coexpression, CD20
bright
 expression and/or CD23 
negativity, light chain restriction with 
moderate/bright sIg expression;  
iii) non-CLL phenotype: CD5 negativity, expression 
of CD20, light chain restriction with 
moderate/bright sIg expression. In atypical 
forms, it is mandatory to exclude t(11;14) to rule 
out mantle cell lymphoma.  
 
TABLE I. DIAGNOSTIC CRITERIA  
FOR MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) 
 
1) Detection of a monoclonal B-cell population in the peripheral 
blood with light chain restriction 
2) Presence of a disease-specific immunophenotype 
3) Absolute B-cell count less than 5 x 109/L 
4) No other features of lymphoproliferative disorder (no lymph 
nodes, spleen and/or liver enlargement, no B-symptoms, such 
as fever, weight loss or nighttime sweating) 
5) No autoimmune or infectious disease 
 
 
The differential diagnosis includes small lymphocytic 
lymphoma (SLL), where the number of circulating 
neoplastic B-cells may be  less than 5 x 10
9
/L. However, 
the presence of lymph nodes, liver or spleen enlargement 
is a typical feature of SLL (Table 2).  
Gibson et al. have also  proposed the definition of 
‘nodal MBL’ to indicate a subsets of patients with fewer 
than 5x10
9
/L circulating clonal B-lymphocytes and a 
focal/subtle abnormal CLL-like infiltration [8].  
Based on the observation that the absolute number of 
B-cells identifies those patients who will require treatment 
from those patients who will not better than  the absolute 
lymphocyte count, in 2008 the diagnostic criteria of CLL 
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have been revised setting the diagnostic threshold of 
neoplastic B-cells in peripheral blood to higher than 5 x 
10
9
/L [7]. As a matter of the fact, a significant number of 
patients previously recognized as having Rai stage 0 CLL 
have been re-classified with CLL-like MBL. Thus, the 
distinction between MBL and Rai stage 0 CLL resides 
only on the number of absolute neoplastic B-cells. 
Moreover, Landgren et al. demonstrated that virtually all 
patients with CLL have a CLL-type MBL phase  several                                                 
years before the CLL diagnosis [5]. Several researchers 
have tried to compare the outcome of the two forms of 
lymphoproliferative disorders [3,4,9-13]. Fung et al. 
showed that Rai stage 0 CLL patients and CLL-type MBL 
patients had a similar overall survival, but also that CLL-
type MBL group displayed a lower probability of early 
progression [9]. No difference was found by Faguet et al.  
 
TABLE II. DIFFERENTIAL DIAGNOSIS AMONG  
CLL, MBL AND SLL 
 
 Neoplastic B-cells 
< 5 x 109/L 
Lymph nodes and/or spleen 
and/or liver enlargement 
MBL + - 
CLL - +/- 
SLL + + 
*adapted from Shanafelt et al [1] 
 
 
in terms of disease progression [10]. Shanafelt et al. 
observed no difference in overall survival; however, these 
authors  found that fewer MBL patients required 
treatment and time to treatment was found to be directly 
correlated with the absolute B-cell count [4]. Rawstron et 
al. also did not find any association with overall survival 
or time to first treatment; in this study, however, the B-
cell count at the time of MBL diagnosis was the only 
independent predictive factor of progression in terms of 
lymphocytosis [3]. More recently, Rossi et al reported a 
longer treatment-free survival in MBL patients than in Rai 
stage 0 CLL [11]. Finally, an absolute B-cell count 
ranging from 10 to 11 x 10
9
/L was demonstrated to better 
predict the clinical outcome (time to first treatment),  thus 
suggesting that the threshold of 5 x 10
9
/L B-cells might  
be inadequate [12,13]. 
Taken together, these data indicate  that the number 
of circulating B-cells is a strong predictor of outcome for 
MBL patients and that “clinical” MBL, with respect to 
“low count” MBL, is closely related to CLL and may be 




III.  BIOLOGY OF MBL 
 
    MBL are more common than CLL (see section IV) and, 
as above reported, it is thought that  almost always they 
precede CLL [5]. Therefore,  it is evident that only a small 
population of MBL patients evolve into overt CLL 
overtime. Ghia and Caligaris-Cappio very recently 
reviewed this topic and proposed that the encounter of a 
B-cell carrying intrinsic abnormalities with an appropriate 
external stimulus (i.e., antigen/B-cell receptor interaction) 
may trigger the clonal development of MBL [14]. On the 
other hand, the possibility that external stimuli may 
precede and favors the appearance of genetic 
abnormalities also exists.  Finally, the persistence of  an  
antigenic stimulus inducing  enhanced clone proliferation  
could favors the acquisition of additional genetic 
abnormalities with the possibility that some MBL may 
progress into overt CLL. Interestingly, in hepatitis C-virus 
(HCV) infected patients MBL has been detected in 28,5% 
of subjects [15]. Moreover, its frequency was found 
increased in patients with more advanced disease. 
     Either clinical and population-screening studies 
indicate that MBL, mimicking what observed in 
monoclonal gammopathy of undetermined significance 
(MGUS), display the same chromosomal abnormalities 
and a mutated IgVH status usually seen in low-risk CLL 
[3,11,13,16-18]. The biological indolent behavior of MBL 
is also documented by the rare occurrence of genetic 
lesions predicting poor prognosis in CLL, such as TP53, 
ATM, NOTCH1 and SF3B1 mutations [17-21]. These 
mutations are, in fact,  more frequently detected in the 
later stages of CLL and in Richter syndrome 
transformation [22].  
Regulatory T-cells (Tregs) constitute a small subset 
of cells involved in antitumour immunity and are 
generally increased in patients with CLL [23]. Tregs have 
been  found higher in ‘clinical’ MBL patients with respect 
to healthy subjects, but lower than in CLL patients [24]. It 
has been hypothesized that the progressive increase of 
Treg numbers might contribute both to the clinical 




IV.  PREVALENCE OF MBL 
 
The prevalence of MBL in general population has 
been extensively investigated in large population-based 
studies [1,3,25-29]. As showed in Figure 1, the reported 
prevalence varied widely, ranging from 0.6% to 12%. 
This very large variability is closely related to the 
methodology used to detect MBL cells, in particular the 
number of monoclonal antibodies used (the higher 
number is employed, the higher incidence of MBL is 
found) and that of cells evaluated. In fact, the highest  
incidence was found by Salamanca group study in which 
eight-color staining panels were utilized  and a greater 
number of cells analyzed (5 million per case versus 
200.000 to 500.000 in the other studies) [28].  
Interestingly, in a study  performed to investigate the 
potential health effects of living around hazardous waste 
sites in the United States [30], the authors suggested that 
MBL may be a potentially useful biomarker for 
investigating environmental exposures potentially 
associated with chronic lymphoproliferative disorders, 
such as CLL. Furthermore, the highest prevalence of 
CLL-like form of MBL was found in first-degree relatives 
Translational Medicine @ UniSa - ISSN 2239-9747 2014, 8(9): 75-79 
 
77 
Università degli Studi di Salerno 
of CLL patients, thus suggesting a higher risk of 




V. NATURAL HISTORY OF MBL AND 
MANAGEMENT 
 
Whether CLL needs of a MBL preceding phase before to 
develop is still matter of debate. Landgren et al, analyzing 
data from 77,469 healthy adults enrolled in the 
nationwide, population-based Prostate, Lung, Colorectal, 
and Ovarian (PLCO) Cancer Screening Trial, identified 
45 subjects who were diagnosed with CLL up to 6.4 years 
later [5]. By evaluating  stored peripheral blood samples, 
these authors were able to demonstrate that 44 out of 45 
patients with CLL had a preceding MBL phase, thus 
suggesting that CLL is almost always preceded by a 
precursor condition, such as MBL.  
Thus, MBL may progress to overt CLL and several 
investigators tried to estimate the frequency of this 
phenomenon [3,4,11]. However, the risk of 
transformation to CLL requiring therapy is very low in 
‘clinical’ MBL, accounting for 1-2% per year, and 
extremely rare in research population-screening MBL 
[17]. Moreover, no specific therapy is established for 
MBL to date and only watch and wait approach for 
clinical MBL is required due to the above mentioned very 
low possible evolution to overt CLL overtime.   
For that reasons, physical examination, patient history, 
whole blood cell count and flow cytometry of peripheral 
blood are mandatory to establish the diagnosis of MBL. 
The majority of investigators recommend a clinical and 
lab (physical examination for lymphadenopathy and 
complete blood cell count with differential) evaluation 
every 6 to 12 months  for patients with ‘clinical’ MBL, 
according to the number of circulating clonal B.cells 
(Table 3). In fact, Rawstron et al showed that more than 
90% of subjects with CLL-like MBL and a cell count 
below 1900 x 10
9
/L will have a stable lymphocytosis over 
a 5-year period [3]. On the other hand, subjects with more 
than 1900 x 10
9
/L clonal B.cells show no disease 
progression Kaplan-Meier curves plateau over time, 







Progresses in flow cytometry with developing of 
more and more highly sensitive techniques have make 
possible to detect abnormal small B-cell clones in 
otherwise asymptomatic subjects. In the so-called ‘low- 
count’ MBL the risk of progression to overt CLL/SLL is 




Figure 1. Prevalence of MBL. Figures on the top of bars showed the incidence (%) of MBL. Figures (in brackets) in x-axis 
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TABLE III. FOLLOW-UP OF MBL CASES 
ACCORDING TO THE NUMBER OF CLONAL B-CELLS 
 
GROUP INTERVAL METHODOLOGY 














On the contrary, in ‘clinical’ MBL the risk of 
progression is estimated to be approximately 1-2% per 
year. No prognostic parameter able to identify subjects 
more prone to evolution compared to subjects with more 
stable lymphocytosis has been so far identified. For that 
reasons, a monitoring of lymphocytosis and/or 
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